UNI-BIO GROUP (00690.HK): Watson Cheng Appointed Group Chief Business Officer

NewTimeSpace News: On 11 November 2026, Uni-Bio Science Group Limited (stock code: 690) published a voluntary announcement that the board has appointed Mr Watson Cheng as Group Chief Business Officer with effect from 11 November 2026.

Mr Cheng has extensive experience in biopharmaceutical investment, mergers and acquisitions, business licensing and cross-border strategic cooperation. Before joining the Group, he was head of international business at ClinActiv, head of healthcare at Harvest Investments, vice president at CBC Group and a director at IQVIA management consulting; his past projects covered multinational product portfolio acquisitions, innovative asset platform building and the privatisation of a North American listed company.

The Group is pursuing an innovation-driven strategic transformation, accelerating international registration and commercialisation of core products and expanding next-generation pipelines through in-house R&D, technology introduction and strategic cooperation, while strengthening retail pharmacy, e-commerce and other out-of-hospital channels. In his new role, Mr Cheng will lead business development and strategic cooperation, maximise the value of the product and pipeline portfolio, bring in strategically complementary products, technologies and pipelines, and advance overseas licensing, co-development and commercialisation as well as strategic investments and acquisitions.